CNS Response cnsresponse.com


Public lists: Medical Devices (6123)

CNS is a company developing and marketing a neurophysiological bio-marker system which can objectively measure the physiological effects of psychiatric drugs on humans.

CNS is a company developing and marketing a neurophysiological bio-marker system which can objectively measure the physiological effects of psychiatric drugs on humans.

Company (Alive / Active)

Phone: 714-545-3288

Fax:

85 Enterprise
Suite 410
Aliso Viejo, 92656
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
CNS Response $8.3M Feb 17, 2011
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related CNS Response Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors

Competitors

Company Status Description Investors

NeuroGenomeX

Madison, Wisconsin, United States
Alive / ActiveNeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in...Show allLogin to see details

Inotek Pharmaceuticals

Lexington, Massachusetts, United States
IPO / Went publicInotek Pharmaceuticals is a biotechnology company focused on the discovery and development of drugs to address serious diseases of the eye. Inotek scientists have identified a deep pipeline of drug candidates to ameliorate inflammation, ischemia-reperfusion injury, and oxidative stress, which are key targets for drugs to treat Glaucoma, Ocular Hypertension, Age-related Macular Degeneration and Retinal Neuropathies. The Company's lead program, trabodenoson (INO-8875) is a highly selective adenosi...Show allLogin to see details
See all 15 competitors